Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: psoriasis

Tashatuvango / shutterstock.com

Myositis-Specific Antibodies Identified

Mithu Maheswaranathan, MD, & Lisa Criscione-Schreiber, MD, MEd  |  January 16, 2020

The idiopathic inflammatory myopathies (IIM) encompass eight categories: 1) dermatomyositis (DM) in adults, 2) juvenile dermatomyositis, 3) amyopathic DM, 4) cancer-associated DM, 5) polymyositis, 6) immune-mediated necrotizing myopathy, 7) inclusion body myositis, and 8) overlap myositis.1 These categories help classify the myopathies based on clinical and histologic features. The incidence of IIM is estimated at…

Filed under:ConditionsMyositis Tagged with:dermatomyositisidiopathic inflammatory myopathiesidiopathic inflammatory myositismyositis-specific antibodiespolymyositis

Novartis, Merck & Allergan Join Those Raising U.S. Drug Prices for 2020

Natasha Yetman  |  January 7, 2020

NEW YORK (Reuters)—Novartis AG, Merck & Co Inc. and Allergan Plc. were among companies that raised U.S. prices on more than 100 prescription medicines on Jan. 4, bringing the tally to 445 drugs that will cost more in 2020, according to data analyzed by healthcare research firm 3 Axis Advisors. That is above the average…

Filed under:Drug Updates Tagged with:costsdrug costDrugs

Ankylosing Spondylitis & Uveitis: An Ophthalmologist’s Perspective

Jason Liebowitz, MD, FACR  |  December 18, 2019

It’s often said the eyes are the window to the soul, and in the case of ankylosing spondylitis and other spondylo­arthropathies, one can also say the eyes are the window to systemic disease. Although uveitis occurs in approximately 2–5% of patients with inflammatory bowel disease, 6–9% of patients with psoriatic arthritis and 25% of patients…

Filed under:Axial SpondyloarthritisConditions Tagged with:Ankylosing SpondylitisAS Resource CenterHLA-B27opthamologistUveitis

The 2019 ACR Award Winners & Distinguished Fellows

Carol Patton  |  December 18, 2019

ATLANTA—Every year at its Annual Meeting, the ACR recognizes its members’ outstanding contributions to the field of rheumatology through an awards program. The ACR is proud to announce 20 award recipients for 2019, honored for their accomplishments as clinicians, instructors or researchers who have helped advance rheumatology, for their commitment to inspire others to enter…

Filed under:AwardsFrom the CollegeProfessional Topics Tagged with:2019 ACR/ARP Annual MeetingDr. Alfred E. DenioDr. Ali Duarte-GarciaDr. Amr H. SawalhaDr. Brian NolanDr. Bruce CronsteinDr. Dana DiRenzoDr. J. Timothy HarringtonDr. Jean LiewDr. John P. AtkinsonDr. Katherine P. LiaoDr. Marcy B. BolsterDr. Mazen NasrallahDr. Michael A. PaleyDr. Natalie RosenwasserDr. Patricia KatzDr. Polly FergusonDr. Rebecca HabermanDr. Sarah ChenDr. Susan ManziJonathan TL Cheah

Hair dye being applied to a man’s beard.

Case Report: A 50-Year-Old Man Suffers Dye-Induced Arthritis

Hrudya Abraham, MD, Eric Warm, MD, FACP, & Avis Ware, MD  |  December 18, 2019

Hair dye products are commonly used by both men and women to enhance youth and beauty and to follow fashion trends. As reported in the medical literature, hair dyes and their ingredients are associated with allergic contact dermatitis. A possible association with joint inflammation has also been recognized. There is literature to support that para-phenylenediamine…

Filed under:Conditions Tagged with:case reportenvironmental factorpara-phenylenediamine (PPD)

FDA Approves Amgen’s Infliximab Biosimilar Treatment

Reuters Staff  |  December 10, 2019

(Reuters)—The U.S. Food and Drug Administration on Friday approved Amgen Inc.’s biosimilar copy of Johnson & Johnson’s blockbuster rheumatoid arthritis drug, Remicade (infliximab), according to the regulator’s website. The biosimilar, Avsola (infliximab-axxq), has the same chemical components, dosage form and strength as Remicade and would treat a range of autoimmune disorders. The label for the…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Avsolainfliximabinfliximab biosimilarinfliximab-axxqRemicadeREMICADE (infliximab)U.S. Food and Drug Administration (FDA)

Rituximab-abbs Available in the U.S.; Plus Upadacitinib in Phase 3 Trials for PsA

Michele B. Kaufman, PharmD, BCGP  |  November 25, 2019

Rituximab-abbs, which is biosimilar to rituximab, is now available in the U.S. to treat specific cancers…

Filed under:Biologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:Cancernon-Hodgkin’s lymphomaPsoriatic Arthritisrituximabrituximab-abbsupadacitinib

A Rash of Evidence: Evaluating & Treating Psoriatic Arthritis

Jason Liebowitz, MD, FACR  |  November 20, 2019

ATLANTA—As many rheumatologists will recall, it was not too long ago that psoriatic arthritis was regarded somewhat like “rheumatoid arthritis with a rash,” with little attention paid to the ways in which the unique pathophysiology and manifestations of this entity make it distinct from other forms of inflammatory arthritis. At the 2019 ACR/ARP Annual Meeting…

Filed under:ConditionsPsoriatic Arthritis Tagged with:2019 ACR/ARP Annual MeetingPsoriatic Arthritis

Year in Review: Rheumatic Disease Research in 2019

Thomas R. Collins  |  November 20, 2019

ATLANTA—Encouraging data on interleukin (IL) 23/IL-17 pathway drugs in psoriatic arthritis (PsA), JAK inhibitors in rheumatoid arthritis (RA) treatment and new evidence on physical activity and bone health in women were among the highlights of the 2019 ACR/ARP Annual Meeting’s Clinical Year in Review. Susan Manzi, MD, MPH, director of the Lupus Center for Excellence…

Filed under:ConditionsOsteoarthritis and Bone DisordersResearch Rheum Tagged with:2019 ACR/ARP Annual MeetingFracturesJAK inhibitorsKnee Osteoarthritis (OA)physical activityPsoriatic ArthritisResearch

Figures 1 & 2: Transverse and longitudinal ultrasound views, respectively, of the left posterior knee, revealing a cystic mass with heterogeneous internal echotexture and no stalk.

Ultrasound Aids Diagnosis of Man with Knee Pain & Swelling

Mark H. Greenberg, MD, RMSK, RhMSUS, Prem Patel, Elijah Mitcham, MD, James W. Fant Jr., MD, & Frank R. Voss, MD  |  November 17, 2019

A 56-year-old automobile mechanic was referred to our rheumatology service by his orthopedist to evaluate left posterior knee pain and swelling that had been present for three months. The patient had undergone bilateral total knee arthroplasties (TKAs) for sports-related osteo­arthritis three years before. In addition to the knee pain, the patient described several years of…

Filed under:ConditionsRheumatoid Arthritis Tagged with:knee arthroplastyknee swellingpopliteal cystsynovitis

  • « Previous Page
  • 1
  • …
  • 22
  • 23
  • 24
  • 25
  • 26
  • …
  • 55
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences